TIDMABC
RNS Number : 7333B
ABCAM Plc
02 November 2009
+---------------------------------------+------------------------------------------+
| For immediate release | 2 November 2009 |
+---------------------------------------+------------------------------------------+
ABCAM PLC
("Abcam" or "the Company")
AGM Statement
Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets
antibodies via its own online catalogue, is holding its Annual General Meeting
at 10.00 am this morning. As previously announced the Company's Chairman, David
Cleevely, will be retiring from the Board at the AGM. Dr Cleevely will make the
following statement at the meeting:
"I am very proud of Abcam's achievements since we established the Company 11
years ago. We have built a global business characterised by rapidly increasing
demand for its products and a strong customer base. In recent times the strength
of our business model has come to the fore and the robust and defensive nature
of the markets we serve has been demonstrated."
"I am pleased to report that the Company has continued to perform well in the
new financial year. Underlying sales growth is in line with our expectations as
demand for our products increases and we are benefiting from the weakness of
sterling over the comparative period last year. The challenges to the global
economy as a result of the recession require a degree of caution, but the Board
looks forward to another successful year."
For further information please contact:
Abcam + 44 (0) 1223 696000
Jonathan Milner, Chief Executive Officer
Jeff Iliffe, Chief Financial Officer
www.abcam.com
Numis Securities + 44 (0) 20 7260 1000
Michael Meade / Nick Westlake - Nominated Adviser
James Black - Corporate Broking
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court / Stasa Filiplic
Notes for editors
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered
in Cambridge, United Kingdom, with offices in Cambridge, Massachusetts, USA,
Tokyo, Japan and Hong Kong. Abcam was admitted to AIM in November 2005 and
trades under the ticker symbol ABC. The Company produces and distributes its own
and third-party produced antibodies to academic and commercial users throughout
the world. Product ordering is available through the Company's website
www.abcam.com, where customers are also able to access up-to-date and detailed
technical product data sheets. All the antibodies are sold under the Abcam brand
name and the Company's vision is to build the world's largest online resource of
high-quality and commercially viable antibodies. Abcam now has an online
catalogue of over 56,000 products, most of which are antibodies, from over 250
suppliers and employs 243 staff in its four operating companies.
About antibodies
Antibodies are proteins produced by white blood cells in response to the
introduction of a foreign body known as an antigen. Antibodies, which have a
wide variety of uses in research, diagnostics and therapeutics, are used by
bioscientists in research into disease and into the human genome, where they are
used to mark and identify specific cells and other living matter. The number of
human antibodies of use in research is potentially greater than one million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGMCKDKBABDDCDK
|